A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Utomilumab in Subjects with Refractory Large B-Cell Lymphoma
Study of Axicabtagene Ciloleucel in Combinataion with Utomilumab in Subjects with Refractory Large B-Cell Lymphoma
Sponsor: Kite Pharma, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS0322
U.S. Govt. ID: NCT03704298
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of this research study is to determine if the experimental treatment, axicabtagene ciloleucel in combination with utomilumab, is safe and effective in treating individuals with Large B-cell Lymphoma. Axicabtagene ciloleucel is manufactured using your own blood cells. Utomilumab is a molecule (protein) which interacts with a specific region called 4-1BB on CAR T cells such as axicabtagene ciloleucel. Research suggests that this interaction may stimulate the CAR T cells to increase in number, become more active and stay alive longer, thus improving cancer fighting ability of CAR T cells. Approximately 48 subjects at approximately 8 clinics will participate in the study.
This study is closed
Ran Reshef, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with large B-cell lymphoma? Yes No
Ha your disease had no response to at least 2 lines of prior therapy (such as radiation or chemotherapy)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator